Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial to Evaluate the Tolerability、Pharmacokinetics and Preliminary Antitumor Activity of FCN-338 in Patients With CLL/SLL

NCT04682808 is registered in ClinicalTrials.gov with Fochon Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT04682808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial to Evaluate the Tolerability、Pharmacokinetics and Preliminary Antitumor Activity of FCN-338 in Patients With CLL/SLL
Lead sponsor
Fochon Pharmaceuticals, Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 13, 2021
Completion date
December 31, 2024
Enrollment
99 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, small lymphocytic lymphoma